- Home
- PEO vs IMTX Comparison
PEO vs IMTX Comparison
Compare PEO & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEO
- IMTX
- Stock Information
- Founded
- PEO 1929
- IMTX N/A
- Country
- PEO United States
- IMTX Germany
- Employees
- PEO N/A
- IMTX N/A
- Industry
- PEO Finance/Investors Services
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEO Finance
- IMTX Health Care
- Exchange
- PEO Nasdaq
- IMTX Nasdaq
- Market Cap
- PEO 596.4M
- IMTX 579.8M
- IPO Year
- PEO N/A
- IMTX N/A
- Fundamental
- Price
- PEO $20.27
- IMTX $6.22
- Analyst Decision
- PEO
- IMTX Strong Buy
- Analyst Count
- PEO 0
- IMTX 4
- Target Price
- PEO N/A
- IMTX $14.67
- AVG Volume (30 Days)
- PEO 35.4K
- IMTX 626.4K
- Earning Date
- PEO 01-01-0001
- IMTX 05-13-2025
- Dividend Yield
- PEO 5.93%
- IMTX N/A
- EPS Growth
- PEO N/A
- IMTX N/A
- EPS
- PEO N/A
- IMTX N/A
- Revenue
- PEO N/A
- IMTX $155,801,989.00
- Revenue This Year
- PEO N/A
- IMTX N/A
- Revenue Next Year
- PEO N/A
- IMTX $5.38
- P/E Ratio
- PEO N/A
- IMTX N/A
- Revenue Growth
- PEO N/A
- IMTX 93.56
- 52 Week Low
- PEO $19.22
- IMTX $3.30
- 52 Week High
- PEO $23.80
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- PEO 49.21
- IMTX 67.73
- Support Level
- PEO $19.90
- IMTX $4.93
- Resistance Level
- PEO $20.59
- IMTX $5.31
- Average True Range (ATR)
- PEO 0.34
- IMTX 0.37
- MACD
- PEO 0.01
- IMTX 0.08
- Stochastic Oscillator
- PEO 39.84
- IMTX 98.33
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a closed-end equity investment company specializing in energy and other natural resources stocks. The investment objectives of the fund are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. Its portfolio of investments comprises of different sector investments such as in the energy sector and basic materials.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.